 Evelo Biosciences Inc NASDAQ: EVLO has announced data from its Phase 2 study of EDP1815 for mild and moderate psoriasis. A statistically significant reduction in the Psoriasis Area and Severity Index PASI score from baseline at week 16 was observed in the study. 